SCHEMBL21724596

SCHEMBL21724596

CCCCCCCC(=O)N[C@@H]([C]=O)CCC(N)=O

nearest known ligand 0.51

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
FAAH O00519 4/20 0.51
MEN1 O00255 3/20 0.51
KMT2A Q03164 3/20 0.51
MAPK1 P28482 1/20 0.51
DNM1 Q05193 1/20 0.50
NOD1 Q9Y239 4/20 0.47
PLA2G2C Q5R387 1/20 0.47
SOAT1 P35610 2/20 0.44
TP53 P04637 1/20 0.44
CYP1A2 P05177 1/20 0.44
CYP3A4 P08684 1/20 0.44
CYP2C19 P33261 1/20 0.44
PLA2G10 O15496 2/20 0.43
HSP90AA1 P07900 1/20 0.43
SLC6A5 Q9Y345 2/20 0.41
KDM4E B2RXH2 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21724553 1.00 FAAH (0.51) FAAHMEN1KMT2AMAPK1DNM1
SCHEMBL21724212 1.00 FAAH (0.51) FAAHMEN1KMT2AMAPK1DNM1
SCHEMBL21724190 0.98 FAAH (0.49) FAAHMEN1KMT2AMAPK1DNM1
SCHEMBL21724570 0.87 CTSD (0.39) FAAHMEN1KMT2AMAPK1DNM1
SCHEMBL21724234 0.86 FAAH (0.53) FAAHMEN1KMT2AMAPK1DNM1
SCHEMBL21724591 0.86 FAAH (0.53) FAAHMEN1KMT2AMAPK1DNM1
SCHEMBL21724161 0.86 FAAH (0.53) FAAHMEN1KMT2AMAPK1DNM1
SCHEMBL20876509 0.86 PLA2G2C (0.63) FAAHMEN1KMT2AMAPK1NOD1
SCHEMBL21724603 0.86 PLA2G2C (0.63) FAAHMEN1KMT2AMAPK1NOD1
SCHEMBL21724501 0.86 PLA2G2C (0.63) FAAHMEN1KMT2AMAPK1NOD1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3836971-A1 CONJUGATES AND METHODS OF USING THE SAME Flagship Pioneering Innovations V, Inc. (US) 2021-06-23 EP claimed
US-20210162057-A1 CONJUGATES AND METHODS OF USING THE SAME FLAGSHIP PIONEERING INNOVATIONS V, INC. 2021-06-03 US claimed
WO-2020037009-A1 CONJUGATES AND METHODS OF USING THE SAME FLAGSHIP PIONEERING INNOVATIONS V, INC. (US) 2020-02-20 WO claimed
US-11998610-B2 Conjugates and methods of using the same FLAGSHIP PIONEERING INNOVATIONS V, INC. (US) 2024-06-04 US disclosed
EP-3836971-A1 CONJUGATES AND METHODS OF USING THE SAME Flagship Pioneering Innovations V, Inc. (US) 2021-06-23 EP disclosed
US-20210162057-A1 CONJUGATES AND METHODS OF USING THE SAME FLAGSHIP PIONEERING INNOVATIONS V, INC. 2021-06-03 US disclosed
WO-2020037009-A1 CONJUGATES AND METHODS OF USING THE SAME FLAGSHIP PIONEERING INNOVATIONS V, INC. (US) 2020-02-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11998610-B2 Conjugates and methods of using the same CD47, CD44, CD74 FAAH 2742/4885MEN1 2346/4885KMT2A 3520/4885
US-20210162057-A1 CONJUGATES AND METHODS OF USING THE SAME CD47, CD44, CD74 FAAH 2742/4885MEN1 2346/4885KMT2A 3520/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.